Publications and Presentations
2016
Journal articles
Kimel M, Leidy NK, Tschosik E, Dolan C, Souied EH, Varma R, Bressler NM. Functional Reading Independence (FRI) Index: A new patient-reported outcome measure for patients with Geographic Atrophy. Invest Ophthalmol Vis Sci. 2016 Nov 1; 57(14):6298-6304
Suňer IJ, Bressler NM, Varma R, Dolan CM, Ward J, Turpcu A. Responsiveness of the national eye institute visual function questionnaire-25 to visual acuity gains in patients with diabetic macular edema: evidence from the RIDE and RISE trials. Retina 2016 Sep23. [Epub ahead of print].
Nussbaum N, George DJ, Abernethy AP, Dolan CM, Oestreicher N, Flanders S, Dorff TB. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. Prostate Cancer Prostatic Dis. 2016 June;19(2):111-21.
Bressler NM, Varma R, Mitchell P, Suňer IJ, Dolan C, Ward J, Ferreira A, Ehrlich JS, Turpcu A. Effect of Ranibizumab on the decision to drive and vision function relevant to driving in patients with diabetic macular edema: report from RESTORE, RIDE and RISE trials. JAMA Ophthalmol. 2016 Feb; 134(2):160-6.
Presentations at scientific meetings
Kapre A, Tschosik E, Kimel M, Chabi A, Dolan C, Sivaprasad S, Bressler N, Varma R. Reliability and convergent validity of the NEI VFQ-25 with and without near and distance activity appendix items in patients with geographic atrophy secondary to age-related macular degeneration. Presented at the ISPOR 19th Annual European Congress, October 2016; Vienna, Austria [Abstr PSS56]
Sivaprasad S, Varma R, Bressler NM, Silverman D, Kimel M, Tschosik, Dolan C. Reliability and construct validity of National Eye Institute Visual Function Questionnaire-25 in Geographic Atrophy. Presented at the ARVO 2016 Annual Meeting, [Poster A0286]
Sivaprasad S, Bressler N, Silverman D, Dolan C, Tschosik E, Kimel M, Varma R. NEI VFQ-25 responsiveness to changes in area of geographic atrophy in patients with age-related macular degeneration. Presented at the 16th EURETINA Congress, September 2016; Copenhagen [Poster]
Bressler NM, Chabi A, Tschosik E, Dolan CM, Kimel M, Varma R. NEI VFQ-25 responsiveness to changes in area of Geographic Atrophy in patients with age-related macular degeneration. Presented at the Retina Society 49th annual meeting; September 2016; San Diego, CA.
2015
Journal articles
Varma R, Bressler NM, Doan QV, Danese M, Dolan CM, Lee A, Turpcu A. Visual impairment and blindness avoided with ranibizumab in Hispanic and non-Hispanic whites with diabetic macular edema in the United States. Ophthalmology. 2015 May;122(5):982-9.
Presentations at scientific meetings
Varma R, Souied E, Tschosik E, Ferrara D, Zhang J, Dolan C, Bressler N. Geographic atrophy lesion size: relationship to maximum reading speed in patients through 18 months. Presented at the American Academy of Ophthalmology, October 2015.
Tschosik E, Leidy NK, Kimel M, Dolan C, Souied E, Varma R, Bressler NM. Quantifying functional reading independence in geographic atrophy: the FRI Index. 2015 ARVO annual meeting abstract. Investigative Ophthalmology & Visual Science June 2015, Vol. 56, 4789
Kapre A, Kimel M, Bressler NM, Varma R, Souied E, Dolan C, Tschosik E, Leidy NK. Sensitivity of the Functional Reading Independence Index to change in size of geographic atrophy. Presented at the International Society for Pharmacoeconomics and Outcomes Research 20th Annual International Meeting, Philadelphia, PA, May 2015.
2014
Journal articles
Bressler NM, Varma R, Suňer IJ, Dolan CM, Ward J, Ehrlich JS, Colman S, Turpcu A; RIDE and RISE Research Groups. Vision-related function after ranibizumab treatment for diabetic macular edema; results from RIDE and RISE. Ophthalmology. 2014 Dec; 121(12):2461-72.
Varma R, Bressler NM, Doan QV, Gleeson M, Danese M, Bower JK, Selvin E, Dolan C, Fine J, Colman S, Turpcu A. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014 Nov;132(11):1334-40.
Mitchell P, Bressler N, Doan QV, Dolan C, Ferreira A, Osborne A, Rochtchina E, Danese M, Colman S, Wong TY. Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. PLoS One. 2014 Jun 30;9(6): e101072.
Bressler NM, Varma R, Doan QV, Gleeson M, Danese M, Bower JK, Selvin E, Dolan C, Fine J, Colman S, Turpcu A. Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States. JAMA Ophthalmol. 2014 Feb;132(2):168-73.
2013
Journal articles
Bressler NM, Chang TS, Varma R, Suñer I, Lee P, Dolan CM, Ward J, Ianchulev T, Fine J.
Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab. Ophthalmology. 2013 Jan;120(1):160-8.
Suñer IJ, Bressler NM, Varma R, Lee P, Dolan CM, Ward J, Colman S, Rubio RG.
Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
JAMA Ophthalmol. 2013 Jul;131(7):851-6.
Presentations at scientific meetings
Bressler N, Varma R, Suñer I, Dolan C, Ward J, Fine J, Turpcu A, Colman S. Effect of monthly vs PRN dosing with ranibizumab on patient-reported visual function for subfoveal neovascular age-related macular degeneration. Presented at the American Society of Retina Specialists, August 2013.
Suñer, NM Bressler, R Varma, C Dolan, J Ward, A Turpcu, G Sternberg, S Colman Improved contrast sensitivity in RVO patients after treatment with ranibizumab in BRAVO and CRUISE. Presented at the American Society of Retina Specialists, August 2013.
Turpcu A, Bergenstal R, Bressler N, Varma R, Bower J, Selvin E, Gleeson M, Danese M, Dolan C, Fine J, Colman S, Doan Q. Risk factors for diabetic retinopathy severity. Presented at the American Diabetic Association, June 2013.
Varma R, Bressler N, Doan Q, Bower J, Selvin E, Gleeson, Danese M, Dolan C, Fine J, Colman S, Turpcu A. Awareness of diabetic retinopathy and eye exams in the US based on NHANES 2005-2008. Presented at the American Diabetic Association, June 2013.
Varma R, Bressler N, Dolan C, Yau L, Ward J, Colman S. Baseline Predictors of improvement in self-reported visual function following treatment with ranibizumab in patients with diabetic macular edema. Presented at the Association for Research in Vision and Ophthalmology, May 2013.
Bressler N, Varma R, Doan Q, Bower J, Selvin E, Gleeson M, Danese M, Dolan C, Fine J, Colman S, Turpcu A. Visual acuity in U.S. adults with diabetic retinopathy: Findings from the 2005-2008 National Health and Nutrition Examination Survey. Presented at the Macula Society, February 2013.
2012
Journal articles
Orr P, Rentz AM, Margolis MK, Revicki DA, Dolan CM, Colman S, Fine JT, Bressler NM. Author response: Validation of the National Eye Institute Visual Function Questionnaire-25 (NEIVFQ-25) in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012 Dec 3;53(13):7950.
Varma R, Bressler NM, Suñer I, Lee P, Dolan CM, Ward J, Colman S, Rubio RG; BRAVO and CRUISE Study Groups. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology. 2012 Oct;119(10):2108-18.
Presentations at scientific meetings
Varma R, Bressler N, Doan Q, Gleeson M, Lee P, Danese M, Dolan C, Fine J, Ehrlich J, Colman S, Turpcu A. African Americans at highest risk of diabetic macular edema compared with non-Hispanic whites and Hispanics. Presented at the American Academy of Ophthalmology, November 2012.
Bressler N, Varma R, Doan Q, Gleeson M, Danese M, Bower J, Selvin E, Dolan C, Fine J, Colman S, Turpcu A. Relationship of diabetic macular edema to eye care from the 2005 to 2008 National Health and Nutrition Examination Survey (NHANES). Presented at the Retina Society, October 2012.
Suñer I, Bressler N, Varma R, Lai P, Dolan C, Ward J, Colman S. The HARBOR study: Effect of monthly vs PRN dosing with ranibizumab (2.0 mg vs. 0.5 mg) on patient-reported visual function in subfoveal neovascular age-related macular degeneration. Presented at the Retina Society, October 2012.
Bressler N, Varma R, Doan Q, Lee P, Suñer I, Danese M, Dolan C, Turpcu A, Ehrlich J, Colman S. Estimated cases of vision impairment or legal blindness avoided in the United States with ranibizumab for central-involved diabetic macular edema with vision loss. Presented at the American Society of Retina Specialists, August 2012.
Bressler N, Varma R, Lee P, Suñer I, Dolan C, Ward J, Ehrlich J, Colman S. Impact of ranibizumab on driving and difficulty driving reported by patients with diabetic macular edema. Presented at the Macula Society, June 2012.
Varma R, Bressler N, Doan Q, Lee P, Suñer I, Danese M, Dolan C, Turpcu A, Lee A, Ehrlich J, S. Colman. Estimated cases of vision-threatening diabetic retinopathy avoided using ranibizumab for visually impairing diabetic macular edema in the United States Presented at the American Diabetes Association, June 2012.
Bressler N, Varma R, Lee P, Suñer I, Dolan C, Ward J, Petrillo J, Ehrlich J, Colman S.Impact of ranibizumab on driving and difficulty driving reported by patients with diabetic macular edema. Presented at the Meeting of the Club Jules Gonin, June 2012.
Oestreicher N, Bressler N, Colman S, Dolan C, Leidy N, Sunness J, Tschosik E, Varma R, Kimel M. The Functional Reading Independence Index (FRII): A new measure of treatment benefit in geographic atrophy. Presented at the Association for Research in Vision and Ophthalmology, May 2012.
Turpcu A, Colman S, Suñer I, Bressler N, Varma R, Lee P, Dolan C, Ward J, Linda Y. The responsiveness of the National Eye Institute Visual Function Questionniare-25 (NEI VFQ-25) to visual acuity gains in diabetic macular edema patients. Presented at the Association for Research in Vision and Ophthalmology, May 2012.
Varma R, Bressler N, Doan Q, Lee P, Suñer I, Danese M, Dolan C, Turpcu A, Ward J, Ehrlich J. Cases of legal blindness and visual impairment avoided using ranibizumab for diabetic macular edema in the United States. Presented at the Association for Research in Vision and Ophthalmology, May 2012.
Varma R, Mitchell P, Bressler N, Lee P, Suñer I, Bandello F, Dolan C, Ward J, Shaw D, Gallagher M, Colman S. Vision-related function after ranibizumab treatment for diabetic macular edema (DME): Clinical trial results from RESTORE, RIDE, and RISE. Presented at the World Ophthalmology Congress, February 2012.
2011
Journal articles
Bressler NM, Doan QV, Varma R, Lee PP, Suñer IJ, Dolan C, Danese MD, Yu E, Tran I, Colman S. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011 Jun;129(6):709-17
Orr P, Rentz AM, Margolis MK, Revicki DA, Dolan CM, Colman S, Fine JT, Bressler NM. Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011 May 18;52(6):3354-9.
Presentations at scientific meetings
Mitchell P, Bressler N, Wong T, Dolan C, Gallagher M, Fereira A, Osborne A, Doan Q, Rochtchina E. Estimated cases of legal blindness and visual impairment from wet age related macular degeneration avoided in Australia because of ranibizumab treatment. Presented at the Royal Australian and New Zealand College of Ophthalmologists, November 2011.
Bressler N, Mitchell P, Varma R, Lee P, Dolan C, Ward J, Shaw D, Gallagher M, Colman S, Osborne A. Vision-related function after ranibizumab treatment for diabetic macular edema by better- or worse-seeing eyes: Clinical trial results from RESTORE, RIDE, and RISE. Presented at the Retina Society, September 2011.
Suñer I, Bressler N, Varma R, Lee P, Dolan C, Ward J, Ehrlich J, Colman S. Effects of ranibizumab on reading Speed through 24 months in patients with vision impairment from diabetic macular edema. Presented at the Retina Society, September 2011.
Bressler N, Varma R, Lee P, Dolan C, Ward J, Suner I, Ehrlich J, Colman S for the RIDE and RISE Study Groups. Effects of ranibizumab on patient-reported visual function through 24 months in patients with vision impairment from diabetic macular edema. Presented at the American Society of Retina Specialists, August 2011.
Varma R, Bressler N, Suñer I, Lee P, Ward J, Dolan C, Colman S. Patients with Neovascular AMD treated with ranibizumab report improvement in function and performing everyday activities in the MARINA Study. Presented at the Association for Research in Vision and Ophthalmology, May 2011.
2010
Journal articles
Bressler NM, Chang T, Suñer I, Fine JT, Dolan CM, Ward J, Ianchulev T for the MARINA and ANCHOR Research Groups. Vision-related function after ranibizumab treatment by better- or worse-seeing Eye: Clinical trial results from MARINA and ANCHOR. Ophthalmology 2010;117:747-756.
Presentations at scientific meetings
Varma R, Bressler N, Suñer I, Lee P, Dolan C, Ward J, Colman S. Improvement in patient-reported driving ability after ranibizumab therapy in neovascular AMD patients. Presented at the Joint Meeting of the American Academy of Ophthalmology and the Middle East Africa Council of Ophthalmology, October 2010.
Bressler N, Varma R, Suñer I, Lee P, Dolan C, Ward J, Colman S, Rubio R, for the BRAVO and CRUISE Study Groups. Effects of ranibizumab on patient-reported visual function through 12 months in patients with macular edema following retinal vein occlusion. Presented at the American Society of Retina Specialists, September 2010.
Bressler N, Suñer I, Lee P, Varma R, Dolan C, Ward J, Colman S. Driving ability in neovascular age-related macular regeneration patients following treatment with ranibizumab: Self-reported perceptions and relevant visual acuities. Presented at the Retina Society, September 2010.
Suñer I, Varma R, Bressler N, Lee P, Dolan C, Ward J, Colman S, Rubio R, for the BRAVO and CRUISE Study Groups. Improvements in reading speed after 6 months of ranibizumab treatment in BRAVO and CRUISE. Presented at the Association for Research in Vision and Ophthalmology, May 2010.
Varma R, Bressler N, Suñer I, Lee P, Dolan C, Ward J, Colman S, Rubio R, for the BRAVO and CRUISE Study Groups. Ranibizumab improves patient-reported near and vision activities in patients with macular edema following retinal vein occlusion. Presented at the Association for Research in Vision and Ophthalmology, May 2010.
Bressler N, Varma R, Lee P, Suñer I, Dolan C, Ward J, Colman S, Rubio R, for the BRAVO and CRUISE Study Groups. Vision-related patient-reported outcomes in BRAVO and CRUISE. Presented at the Macula Society, February 2010.
2009
Journal articles
Suñer I, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. NEI VFQ-25 is responsive to changes in visual acuity in neovascular AMD: Results of validation studies using data from 2 Phase 3 clinical trials. Investigative Ophthalmology and Visual Science 2009;50:3629-3635.
Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J for the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group. Improved vision-related function after ranibizumab vs photodynamic therapy: A randomized clinical trial. Archives of Ophthamology 2009;127:13-21.
Presentations at scientific meetings
Suñer I, Bressler N, Lee P, Dolan C, Colman S, Fine J, Ward J. Vision-related mental health changes in response to ranibizumab therapy in MARINA and ANCHOR. Presented at the American Academy of Ophthalmologists, October 2009.
Bressler N, Varma R, Lee P, Suñer I, Danese M, Yu E, Dolan C, Tran I, Doan Q. Estimated cases of legal blindness avoided in the United States with ranibizumab for neovascular age-related macular degeneration. Presented at the combined meeting of the Macula Society, Retina Society, and American Society of Retina Specialists, October 2009.
Michels M, Brown D, Ward J, Colman S, Dolan C, Varma R, Suñer I, Lee P, Bressler N. NEI VFQ-25 outcomes in PIER within subgroups defined by OCT fluid status. Presented at the combined meeting of the Macula Society, Retina Society, and American Society of Retina Specialists, October 2009.
Suñer I, Lee P, Bressler N, Dolan C, Ward J, Ianchulev S. Improved contrast sensitivity in AMD patients after treatment with ranibizumab in MARINA and ANCHOR. Presented at the combined meeting of the Macula Society, Retina Society, and American Society of Retina Specialists, October 2009.
Colman S, Dolan C, Suñer I, Lee P, Bressler N, Wyrwich K, Revicki D, Harnam N. Relationship between reading items of the National Eye Institute Visual Function Questionnaire-25 (VFQ) and reading speed. Presented at the Association for Research in Vision and Ophthalmology, May 2009.
Suñer I, Lee P, Bressler N, Colman S, Dolan C, Ward J. National Eye Institute Visual Function Questionnaire-25 (VFQ) reading items improved following ranibizumab treatment in MARINA and ANCHOR. Presented at the Association for Research in Vision and Ophthalmology, May 2009.
2008
Presentations at scientific meetings
Lee P, Suñer I, Dolan C, Colman S, Ward J, Bressler N. NEI VFQ-25 Vision-related activities pertinent to patients with neovascular AMD. Presented at the American Academy of Ophthalmologists, November 2008.
Suñer I, Bressler N, Lee P, Colman S, Dolan C, Ward J. Neovascular AMD patients in ANCHOR who still drive report more control and less dependence on others than those who do not drive. Presented at the American Society of Retina Specialists, October 2008.
Suñer I, Lee P, Dolan C, Colman S, Ward J, Bressler N. Driving is associated with less vision-related dependency in neovascular AMD patients. Presented at the Retina Society, September 2008.
Bressler NM, Lee P, Dolan C, Colman S, Ward J, Suñer I. Analysis of Observed Disparities Between Visual Acuity and Visual Function Changes: Seemingly Paradoxical Results in ANCHOR. Presented at the Retina Society, September 2008.
Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J, Ianchulev T, for the MARINA and ANCHOR Research Group. Vision-Related Function After Ranibizumab Treatment by Better- or Worse-Seeing Eye: Randomized Clinical Trial Results from MARINA and ANCHOR. Presented at Club Jules Gonin Meeting, September 2008.
Win P, Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J, for the ANCHOR Research Group. Self-Reported Perception of Driving Function After Ranibizumab Therapy in Patients with Neovascular Age-Related Macular Degeneration (AMD). Presented at the Association for Research in Vision and Ophthalmology, May 2008.
Suñer I, Bressler NM, Lee P, Colman S, Dolan CM, Ward J for the ANCHOR Research Group. Relationship of Visual Acuity and NEI VFQ-25 Visual Function in Exudative AMD Treatment. Presented at the Association for Research in Vision and Ophthalmology, May 2008.
Bressler N, Suñer IJ, Lee P, Colman S, Dolan CM, Ward J, for the MARINA Research Group. Seemingly Paradoxical Results from ANCHOR: Relationship Between Changes in Visual Acuity and Patient-Reported Changes in Visual Acuity and Patient-Reported Visual Function Following Treatment of AMD. Presented at the Macula Society, March 2008.
2007
Journal articles
Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR for the MARINA Research Group. Improved vision-related function after ranibizumab treatment of neovascular AMD: Results of a randomized clinical trial. Archives of Ophthalmology 2007;125:1460-1469.
Dolan CM, Kraemer H, Browner W, Ensrud K, Kelsey JK. Associations between body composition, anthropometry, and mortality in women aged 65 years and older. American Journal of Public Health 2007;97:913-918.
Presentations at scientific meetings
Bressler NM, Dolan C, Yu E, Ward J, for the MARINA Research Group. Vision-Related Function After Ranibizumab Treatment by Better- or Worse-Seeing Eye: 24 Month Results from ANCHOR. Presented at the American Society of Retina Specialists, December 2007.
Cooney M, Bressler N, Fine J, Yu E, Dolan C. The Relationship Between The 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25) and Reading Speed and Restricted Activity Days. Presented at the American Society of Retina Specialists, December 2007.
Holekamp N, Bressler N, Chang TS, Fine JT, Dolan CM, Ward J. Self-Reported Perception of Driving Function Following Ranibizumab Treatment in Patients with Neovascular AMD. Presented at Association for Research in Vision and Ophthalmology, December 2007.
Cooney MJ, Bressler NM, Rentz AM, Margolis MK, Revicki D, Dolan CM, Yu EB, Fine JT. Relationship between the National Eye Institute Visual Function Questionnaire-25 and BCVA and contrast sensitivity in patients with AMD. Presented at the American Academy of Ophthalmology, November 2007.
Holekamp N, Bressler NM, Yu EB, Ward JF, Fine JT, Dolan CM, Chang TS. Determining a clinically meaningful change in the visual function questionnaires (VFQ-25) in neovascular AMD using MARINA trial data. Presented at the American Academy of Ophthalmology, November 2007.
Suñer IJ, Bressler NM, Dolan CM, Fine JT, Yu EB, Ward JF. Improvements in patient-reported National Eye Institute Visual Function Questionnaire-25 (VFQ-25) following treatment with ranibizumab in neovascular patients Presented at the American Academy of Ophthalmology, November 2007.
Bressler NM, Fine JT, Dolan C, Ward J, for the MARINA Research Group. Vision-Related Function After Ranibizumab Treatment by Better- or Worse-Seeing Eye: 24 Month Results from ANCHOR, Presented at the Retina Society, September 2007.
Suñer I, Bressler NM, Dolan CM, Fine JT, Yu EB, Margolis MK, Rentz AM, Revicki DA. The Relationship Between the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25) and Performance-Based Tests. Presented at the Retina Society, September 2007.
Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J. Self-reported perception of driving function following ranibizumab in patients with neovascular AMD. Presented at the Association for Research in Vision and Ophthalmology, May 2007.
Suñer IJ, Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. Vision-related function after ranibizuamb (Lucentis™) treatment by better- or worse-seeing eye: 24 month results from ANCHOR. Presented at the Association for Research in Vision and Ophthalmology, May 2007.
Mandava, N, Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. Self-reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Presented at the Macula Society, May 2007.
Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J for the MARINA and ANCHOR Research Group. Evidence that a change of at least 10 letters is a clinically relevant outcome in neovascular AMD. Presented at the Macula Society, May 2007.
2006
Presentations at scientific meetings
Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J for the MARINA Research Group. Vision-related quality of life through 12 months in predominantly classic neovascular AMD: Analysis of ANCHOR: A Phase III randomized trial of ranibizumab and verteporfin PDT. Presented at the Retina Society, October 2006.
Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J for the MARINA Study Group. Ranbizumab versus sham for subfoveal minimally classic or occult (no class) lesions: vision-related quality-of-life findings from MARINA by ‘better-or worse-seeing eye.’ Presented at the Retina Society, October 2006.
Regillo C, Bressler N, Fine J, Dolan C, Marceau, Change T. Vision-specific quality of life at 12 months in subjects with or without classic CNV due to AMD: Phase III clinical trial of ranibizumab (Lucentis™). Presented at the American Society of Retina Specialists, September 2006.
Chang TS, Fine JT, Dolan CM, Marceau C, Bressler NM. Ranibizumab (Lucentis™) vision-specific quality of life through 24 months in neovascular AMD subjects in MARINA: A phase III clinical trial. Presented at the American Society of Retina Specialists, September 2006.
Bressler NM, Fine JT, Dolan CM, Marceau C, Chang TS for the ANCHOR Study Group. Vision-specific quality of life through 12 months in ANCHOR: A Phase III Trial of ranibizumab and verteporfin PDT for predominantly classic neovascular lesions in patients with age-related macular degeneration. Presented at the American Society of Retina Specialists, September 2006.
Chang TS, Fine JT, Dolan CM, Bressler NM. Patient reported visual function results from the MARINA trial. Presented at the Macula Society, February 2006.
